[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607819":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":134,"collaborators":31,"id":136,"slug":31,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":31,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":31,"enrollmentInfo":144,"targetDuration":31,"studyType":147,"phases":148,"briefSummary":151,"conditions":152,"keywords":157,"overallStatus":45,"whyStopped":31,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Avenzo Therapeutics, Inc.","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1, monotherapy","EXPERIMENTAL","Part A",[13],"Drug: AVZO-103",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1, combination","Part B",[13,18],"Drug: Combination Agent",{"label":20,"type":10,"description":11,"interventionNames":21},"Phase 2, monotherapy",[13],{"label":23,"type":10,"description":16,"interventionNames":24},"Phase 2, combination",[13,18],[26,32],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","AVZO-103","Specific dose in protocol specified schedule",[15,9,23,20],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Combination Agent","Per label based on combination agent used",[15,23],[37],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Medical Information","CONTACT","(858) 239-2944","ClinicalTrials@avenzotx.com",[43,56,65,73,82,90,99,108,117,126],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":31},"Avenzo Therapeutics Recruiting Site","RECRUITING","San Francisco","California","94158","United States",{"type":51,"coordinates":52},"Point",[53,54],-122.41942,37.77493,{"lat":54,"lon":53},{"facility":44,"status":45,"city":57,"state":58,"zip":59,"country":49,"cosmosGeoPoint":60,"geoPoint":64,"contacts":31},"Orlando","Florida","32827",{"type":51,"coordinates":61},[62,63],-81.37924,28.53834,{"lat":63,"lon":62},{"facility":44,"status":45,"city":66,"state":58,"zip":67,"country":49,"cosmosGeoPoint":68,"geoPoint":72,"contacts":31},"Tampa","33612",{"type":51,"coordinates":69},[70,71],-82.45843,27.94752,{"lat":71,"lon":70},{"facility":44,"status":45,"city":74,"state":75,"zip":76,"country":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":31},"Boston","Massachusetts","02114",{"type":51,"coordinates":78},[79,80],-71.05977,42.35843,{"lat":80,"lon":79},{"facility":44,"status":45,"city":83,"state":83,"zip":84,"country":49,"cosmosGeoPoint":85,"geoPoint":89,"contacts":31},"New York","10065",{"type":51,"coordinates":86},[87,88],-74.00597,40.71427,{"lat":88,"lon":87},{"facility":44,"status":45,"city":91,"state":92,"zip":93,"country":49,"cosmosGeoPoint":94,"geoPoint":98,"contacts":31},"Chapel Hill","North Carolina","27514",{"type":51,"coordinates":95},[96,97],-79.05584,35.9132,{"lat":97,"lon":96},{"facility":44,"status":45,"city":100,"state":101,"zip":102,"country":49,"cosmosGeoPoint":103,"geoPoint":107,"contacts":31},"Myrtle Beach","South Carolina","29572",{"type":51,"coordinates":104},[105,106],-78.88669,33.68906,{"lat":106,"lon":105},{"facility":44,"status":45,"city":109,"state":110,"zip":111,"country":49,"cosmosGeoPoint":112,"geoPoint":116,"contacts":31},"Nashville","Tennessee","37203",{"type":51,"coordinates":113},[114,115],-86.78444,36.16589,{"lat":115,"lon":114},{"facility":44,"status":45,"city":118,"state":119,"zip":120,"country":49,"cosmosGeoPoint":121,"geoPoint":125,"contacts":31},"Austin","Texas","78758",{"type":51,"coordinates":122},[123,124],-97.74306,30.26715,{"lat":124,"lon":123},{"facility":44,"status":45,"city":127,"state":119,"zip":128,"country":49,"cosmosGeoPoint":129,"geoPoint":133,"contacts":31},"Irving","75039",{"type":51,"coordinates":130},[131,132],-96.94889,32.81402,{"lat":132,"lon":131},{"type":135,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100607819",false,"NCT07193511","BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","A Phase 1\u002F2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4\u002FTrop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","Key Inclusion Criteria:\n\n* Patient must be an adult, 18 years of age and older with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 and a life expectancy of \\> 3 months.\n* Patients with histologically or cytologically confirmed locally advanced\u002Fmetastatic malignancies for tumor types of preferred indications:\n\n  o Locally advanced or metastatic urothelial cancer and other solid tumors (as specified in the protocol).\n* Measurable disease as assessed by Investigator using RECIST v1.1.\n* Agree to provide molecular test report results to confirm eligibility and archival tumor samples and\u002For fresh biopsy, as applicable.\n* Other protocol-defined Inclusion criteria apply.\n\nKey Exclusion Criteria:\n\n* Patients with active central nervous system (CNS) metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate if they are radiologically stable for at least 4 weeks prior to the first dose of this study and do not require steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible, even if treated.\n* Prior Stevens-Johnson syndrome\u002Ftoxic epidermal necrolysis.\n* History of drug-induced interstitial lung disease (ILD).\n* History of any serious cardiovascular condition.\n* Infection requiring IV antibiotics, antivirals, or antifungals within 2 weeks prior to first dose.\n* History of allogenic stem cell or solid organ transplant.\n* Other protocol-defined Exclusion criteria apply.","ALL","18 Years",{"count":145,"type":146},355,"ESTIMATED","INTERVENTIONAL",[149,150],"PHASE1","PHASE2","This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.",[153,154,155,156],"Solid Tumor Cancer","Locally Advanced","Metastatic Solid Tumors","Urothelial Cancer",[158,159,154,156],"Solid Tumors","Metastatic","2026-05-21",{"date":162,"type":163},"2026-05-26","ACTUAL",{"date":165,"type":163},"2025-10-02",{"date":167,"type":146},"2030-09",{"name":5,"class":6},10]